Yahoo · Oct 22, 2026
Biotech Giants vs. Emerging Innovators: Which ETF Is the Better Buy?
Both of these ETFs look the part, but only one is truly the better buy for investors.
XB
NYSE · XBI
SPDR S&P Biotech ETF
Financial Services · Asset Management
$155.98
Down-$1.81 (-1.15%)
Updated Nov 1, 2026, 8:56 AM
SID Score
5.9/10
Composite research score
Smart Money
56/100
Neutral
- Market cap
- 6.38B
- P/E ratio
- —
- Dividend yield
- 0.03%
- 52-week range
- $118.19 – $169.89
- Volume
- 9.1M
- Avg. volume
- 10.76M
Price performance · XBI
XBI price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
XBI closed at $155.98 after 20 trading sessions, down 0.13% for the selected period.
- Last close
- $155.98
- Period change
- -0.13%
- Period low
- $144.32
- Period high
- $157.79
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $156.68 | $159.76 | $154.22 | $155.98 | 9.1M |
| Oct 29, 2026 | $157.64 | $160.29 | $156.43 | $157.79 | 10.93M |
| Oct 28, 2026 | $153.27 | $157.55 | $152.83 | $157.51 | 9.11M |
| Oct 27, 2026 | $150.35 | $154.92 | $149.27 | $154.84 | 8.67M |
| Oct 26, 2026 | $150.42 | $151.83 | $149.49 | $150.47 | 4.82M |
| Oct 23, 2026 | $150.46 | $150.705 | $147.635 | $149.54 | 6.61M |
| Oct 22, 2026 | $152.25 | $154.44 | $149.69 | $151.64 | 11.6M |
| Oct 21, 2026 | $153.37 | $155.78 | $152.69 | $152.78 | 8.3M |
| Oct 20, 2026 | $148.03 | $153.98 | $147.75 | $153.24 | 12.37M |
| Oct 19, 2026 | $145.88 | $148.63 | $145.29 | $147.86 | 8.39M |
| Oct 16, 2026 | $149.89 | $150.225 | $143.8492 | $144.32 | 11.76M |
| Oct 15, 2026 | $147.71 | $150.86 | $146.93 | $149.78 | 11.51M |
| Oct 14, 2026 | $146.17 | $148.82 | $145.26 | $146.77 | 10.38M |
| Oct 13, 2026 | $150.52 | $150.89 | $146.70 | $146.80 | 9.75M |
| Oct 12, 2026 | $153.43 | $154.12 | $151.10 | $151.40 | 6.05M |
| Oct 9, 2026 | $149.32 | $154.50 | $149.03 | $153.77 | 12.14M |
| Oct 8, 2026 | $149.00 | $149.69 | $146.01 | $149.29 | 12.92M |
| Oct 7, 2026 | $149.37 | $152.40 | $148.63 | $150.23 | 9.54M |
| Oct 6, 2026 | $156.87 | $157.47 | $149.68 | $150.90 | 17.22M |
| Oct 5, 2026 | $155.56 | $156.73 | $152.56 | $156.19 | 6.99M |
Latest XBI news
The latest Smart Investors Daily articles mentioning XBI.
Stock researchCompany · Overview
Company
Market Activity
Research & News
XBI research
Overview
Company profile and research snapshot.
Company profile
In seeking to track the performance of the S&P Biotechnology Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology segment of the S&P Total Market Index ("S&P TMI").
Analyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
Yahoo · Oct 20, 2026
Why $55 Million Flowed Into a Triple-Leveraged Biotech ETF Worth Less Than $600 Million
Traders poured tens of millions into a triple-leveraged biotech fund in a single day, a move that looks like bold conviction until you see what that same bet returned over five years.
Yahoo · Oct 14, 2026
UNH Stock Outpaces S&P 500 In 2026, Eyes Best Year Since Pandemic — CFO Says Wall Street May Be Missing 2027 Upside
CFO Wayne DeVeydt called the lower end of the company’s 13% to 16% long-term earnings growth target a “reasonable starting point.”
Yahoo · Oct 12, 2026
Stocktwits Pharma Pulse: JNJ Earnings, Cancer Updates And Two FDA Target Dates — The Week’s Biotech Watchlist
JNJ reports third-quarter results on Tuesday, and Koyfin analysts expect modest revenue growth and lower earnings.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
